-
Something wrong with this record ?
Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients
JM. Hartinger, P. Ryšánek, O. Slanař, M. Šíma
Language English Country England, Great Britain
Document type Journal Article, Review
Grant support
Cooperatio project (research area PHAR)
Univerzita Karlova v Praze
SVV 260523
Univerzita Karlova v Praze
NLK
CINAHL Plus with Full Text (EBSCOhost)
from 1998-02-01
Medline Complete (EBSCOhost)
from 1998-02-01
PubMed
35934622
DOI
10.1111/jcpt.13753
Knihovny.cz E-resources
- MeSH
- Immunosuppressive Agents MeSH
- Humans MeSH
- MTOR Inhibitors MeSH
- Sirolimus * pharmacokinetics therapeutic use MeSH
- TOR Serine-Threonine Kinases MeSH
- Organ Transplantation * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
WHAT IS KNOWN AND OBJECTIVES: mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients. METHODS: Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies. RESULTS AND DISCUSSION: A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization. WHAT IS NEW AND CONCLUSION: The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22024601
- 003
- CZ-PrNML
- 005
- 20240522101900.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jcpt.13753 $2 doi
- 035 __
- $a (PubMed)35934622
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Hartinger, Jan $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic $7 xx0224709
- 245 10
- $a Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients / $c JM. Hartinger, P. Ryšánek, O. Slanař, M. Šíma
- 520 9_
- $a WHAT IS KNOWN AND OBJECTIVES: mTOR inhibitors possess narrow therapeutic range and substantial pharmacokinetic variability and the consequences from suboptimal dosing are serious. The aim of this review is to summarize the current knowledge about the factors influencing mTOR inhibitors pharmacokinetics and the possibility of using these relationships in order to improve its therapy individualization in solid organ transplanted patients. METHODS: Literature search from Pubmed and Web of Science databases were performed using Boolean search operators in order to identify relevant studies. RESULTS AND DISCUSSION: A total of 701 reports were identified from the initial literature search. Out of which 40 studies dealt with relationships between various factors and pharmacokinetics of mTOR inhibitors and with relevance of these associations for dosage optimization. WHAT IS NEW AND CONCLUSION: The overview of the current covariates for pharmacokinetic variability of mTOR inhibitors has been provided on the level of absorption, distribution and elimination, and consequences of these relationships for dosing optimization has been summarized.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $7 D007166
- 650 _2
- $a mTOR inhibitory $7 D000091203
- 650 12
- $a transplantace orgánů $7 D016377
- 650 12
- $a sirolimus $x farmakokinetika $x terapeutické užití $7 D020123
- 650 _2
- $a TOR serin-threoninkinasy $7 D058570
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Ryšánek, Pavel $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic
- 700 1_
- $a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic
- 700 1_
- $a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague 2, Czech Republic $1 https://orcid.org/https://orcid.org/000000026541738X
- 773 0_
- $w MED00007277 $t Journal of clinical pharmacy and therapeutics $x 1365-2710 $g Roč. 47, č. 9 (2022), s. 1362-1367
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35934622 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20240522101856 $b ABA008
- 999 __
- $a ok $b bmc $g 1854367 $s 1175891
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 47 $c 9 $d 1362-1367 $e 20220807 $i 1365-2710 $m Journal of clinical pharmacy and therapeutics $n J Clin Pharm Ther $x MED00007277
- GRA __
- $a Cooperatio project (research area PHAR) $p Univerzita Karlova v Praze
- GRA __
- $a SVV 260523 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20221017